Stephanie Gaddis
Payments from drug & device makers
Across 436 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$610
- Novo Nordisk$580
- AbbVie$547
- AstraZeneca$429
- Novartis$419
- Astellas Pharma US Inc$401
- plus $5K from 45 others
What the payments were for
- Food & beverage$7,39898%
- Education$1001%
- Entertainment$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
How this compares
$7,510 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 58 | $91,706 |
| OzempicSemaglutide | 75 | $86,413 |
| JardianceEmpagliflozin | 63 | $57,175 |
| FarxigaDapagliflozin Propanediol | 69 | $51,094 |
| EliquisApixaban | 58 | $48,585 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $19,507 |
| MyrbetriqMirabegron | 37 | $14,882 |
| InvokanaCanagliflozin | 56 | $14,520 |
| JanuviaSitagliptin Phosphate | 16 | $14,168 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 17 | $12,839 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $11,738 |
| LinzessLinaclotide | 11 | $11,044 |
| VascepaIcosapent Ethyl | 19 | $9,913 |
| BrilintaTicagrelor | 12 | $8,652 |
| NexlizetBempedoic Acid/Ezetimibe | 12 | $8,416 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $246 | $91,70658 claims |
| Novo NordiskOzempic | $580 | $86,41375 claims |
| Boehringer IngelheimJardiance, Tradjenta | $163 | $64,83176 claims |
| AstraZenecaFarxiga, Brilinta | $429 | $59,74681 claims |
| PfizerEliquis | $610 | $48,58558 claims |
| MerckJanuvia, Janumet Xr, Belsomra | $81 | $34,41950 claims |
| Astellas Pharma US IncMyrbetriq | $401 | $14,88237 claims |
| Johnson & JohnsonInvokana | $158 | $14,52056 claims |
| AbbVieLinzess | $547 | $11,04411 claims |
| Esperion Therapeutics, Inc.Nexlizet | $301 | $8,41612 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $31 | $1,796189 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Macon
- Villanueva SpiveyMacon$18K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.